Full-Time
Develops gene-editing therapies using CRISPR
$110k - $120k/yr
South Boston, Boston, MA, USA
Hybrid
At least three days on-site per week required.
Bachelor's
See people who can refer or advise you
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 to treat serious diseases. It edits genes in human cells, either ex vivo or in vivo, to correct disease-causing mutations, focusing on sickle cell disease, cancer, and other genetically defined conditions. The company supports its pipeline through partnerships and licensing in addition to internal R&D and clinical work, rather than relying solely on in-house development. Its goal is to deliver durable, disease-modifying therapies that meet unmet medical needs for patients worldwide through a global biopharmaceutical strategy.
Company Size
201-500
Company Stage
IPO
Headquarters
Switzerland
Founded
2013
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Flexible Work Hours
Hybrid Work Options
Stock Options
401(k) Retirement Plan
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Conference Attendance Budget
Professional Development Budget
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Parental Leave
Paid Vacation
Paid Holidays
Relocation Assistance
Sabbatical Leave
Paid Sick Leave
Employee Discounts
Employee Referral Bonus
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Training Programs
Meal Benefits
Commuter Benefits
Legal Services
Research Collaboration Benefits
CRISPR Therapeutics outlined a busy second-half pipeline and reported strong quarterly growth in its marketed gene therapy. Shares rose 1.4% in after-hours trading on Monday. Updates are expected on a gene-editing treatment for severe high triglycerides and hard-to-control cholesterol, with results to be presented at a major heart conference on 28 August. More data is also anticipated for a blood-clotting therapy and an immune-cell treatment being tested in autoimmune diseases and blood cancers. CASGEVY, the gene therapy for sickle cell disease and a related blood disorder, generated $76 million in second-quarter revenue, a 78% increase from the prior quarter. The FDA recently approved it for children as young as two. Net loss narrowed to $91.2 million from $208.5 million a year earlier.
CRISPR Therapeutics reported second quarter 2026 financial results, with CASGEVY generating $76 million in revenue, representing 78% growth quarter-over-quarter and 151% growth year-over-year. The FDA recently approved CASGEVY for children as young as 2 years with sickle cell disease or transfusion-dependent beta thalassemia, achieved in 53 days post-filing. This approval makes approximately 5,500 additional patients eligible for treatment. The company initiated Phase 1 clinical trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency, expanding its in vivo pipeline. Vertex secured reimbursement for CASGEVY in Germany for eligible patients aged 12 and older. CASGEVY is now approved in 39 countries across North America, Europe, and the Middle East.
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? Erin Kennedy, The Motley Fool
CRISPR Therapeutics rose 11.3% following its addition to several Russell growth indices in late June 2026, including the Russell 2000 Growth, 2500 Growth and 3000 Growth benchmarks. The inclusion increases visibility among benchmarked funds but doesn't alter the company's fundamental profile. The gene-editing company generates only a few million dollars in annual revenue against hundreds of millions in losses, with value concentrated in its clinical pipeline rather than current operations. Its allogeneic CAR T and in vivo editing programmes face ongoing clinical and regulatory milestones. Whilst index inclusion may support liquidity and trading, it doesn't reduce execution, funding or trial risks. Simply Wall St community members' fair value estimates range from $67.82 to $208.83, reflecting divergent views on the loss-making company's prospects.
CRISPR Therapeutics has experienced significant stock volatility this year as investors grapple with its transition from clinical to commercial stage. The company's gene-editing therapy CASGEVY, developed with Vertex Pharmaceuticals and approved in late 2023 for sickle cell disease, generated only $1.46 million in revenue during Q1 2026, whilst posting a $122.9 million net loss. Commercial adoption faces challenges, as gene-editing treatments require specialised centres, complex preparations and lengthy approval processes. However, CRISPR maintains a strong balance sheet with approximately $2.4 billion in cash and marketable securities. The company's investigational CAR-T therapy CTX112 has attracted attention as a potential "off-the-shelf" treatment that could be produced at scale, lowering costs and shortening treatment timelines compared to traditional personalised therapies.